ImmVira's Bladder Cancer Trials: Promising Data Revealed
Tackling Bladder Cancer with Innovation In a world where every budding biotech claims they're on the cusp of revolutionizing cancer treatment, ImmVira's recent data on their oncolytic immunotherapy, MVR-T3011, stands out like a bright flash in a murky market. Presented at the prestigious European Society for Medical Oncology (ESMO) Congress 2026 in Suzhou, these updates...
Continue Reading